VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-2.98%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$251M
AUM Growth
-$19M
(-7%)
Cap. Flow
-$3.64M
Cap. Flow
% of AUM
-1.45%
Top 10 Holdings %
Top 10 Hldgs %
7.1%
Holding
477
New
43
Increased
256
Reduced
137
Closed
41
Top Buys
| 1 |
The Mosaic Company
MOS
|
$900K |
| 2 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
$877K |
| 3 |
Enphase Energy
ENPH
|
$858K |
| 4 |
Gartner
IT
|
$732K |
| 5 |
Devon Energy
DVN
|
$727K |
Top Sells
| 1 |
L3Harris
LHX
|
$740K |
| 2 |
Cheniere Energy
CQP
|
$732K |
| 3 |
Agilent Technologies
A
|
$713K |
| 4 |
Copart
CPRT
|
$688K |
| 5 |
Equifax
EFX
|
$678K |
Sector Composition
| 1 | Healthcare | 18.83% |
| 2 | Real Estate | 17.55% |
| 3 | Materials | 12.77% |
| 4 | Financials | 9.88% |
| 5 | Energy | 9.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
FibroGen
FGEN
$48.9M
| $152K | 0.06% |
466
+3
| +0.6% | +$979 |
|
352
Intellia Therapeutics
NTLA
$1.29B
| $152K | 0.06% |
2,720
+26
| +1% | +$1.45K |
|
353
ALX Oncology
ALXO
$65.3M
| $151K | 0.06% |
15,756
+115
| +0.7% | +$1.1K |
|
354
Denali Therapeutics
DNLI
$2.26B
| $150K | 0.06% |
4,875
+36
| +0.7% | +$1.11K |
|
|
SWTX
355
DELISTED
SpringWorks Therapeutics
SWTX
| $147K | 0.06% |
5,151
+40
| +0.8% | +$1.14K |
|
356
uniQure
QURE
$985M
| $146K | 0.06% |
7,802
+52
| +0.7% | +$973 |
|
357
SuRo Capital
SSSS
$207M
| $146K | 0.06% |
+37,817
| New | +$146K |
|
358
Avidity Biosciences
RNA
$6.48B
| $145K | 0.06% |
8,852
+71
| +0.8% | +$1.16K |
|
359
Keros Therapeutics
KROS
$633M
| $144K | 0.06% |
3,825
+32
| +0.8% | +$1.21K |
|
360
Krystal Biotech
KRYS
$4.35B
| $144K | 0.06% |
2,071
+16
| +0.8% | +$1.11K |
|
|
MORF
361
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $143K | 0.06% |
5,068
+41
| +0.8% | +$1.16K |
|
362
Vaxcyte
PCVX
$4.29B
| $142K | 0.06% |
5,910
+45
| +0.8% | +$1.08K |
|
363
Nurix Therapeutics
NRIX
$758M
| $141K | 0.06% |
10,813
+78
| +0.7% | +$1.02K |
|
364
Regenxbio
RGNX
$490M
| $139K | 0.06% |
5,248
+39
| +0.7% | +$1.03K |
|
|
MRTX
365
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $139K | 0.06% |
1,989
+14
| +0.7% | +$978 |
|
366
IDEAYA Biosciences
IDYA
$2.38B
| $137K | 0.05% |
9,156
+68
| +0.7% | +$1.02K |
|
367
Celldex Therapeutics
CLDX
$1.52B
| $136K | 0.05% |
4,847
+31
| +0.6% | +$870 |
|
368
Xencor
XNCR
$610M
| $136K | 0.05% |
5,220
+35
| +0.7% | +$912 |
|
|
EQRX
369
DELISTED
EQRx, Inc. Common Stock
EQRX
| $136K | 0.05% |
27,494
+205
| +0.8% | +$1.01K |
|
370
BioXcel Therapeutics
BTAI
$55.2M
| $134K | 0.05% |
710
+5
| +0.7% | +$944 |
|
371
Runway Growth Finance
RWAY
$388M
| $134K | 0.05% |
+11,819
| New | +$134K |
|
372
Arcus Biosciences
RCUS
$1.3B
| $133K | 0.05% |
5,068
+39
| +0.8% | +$1.02K |
|
373
Xenon Pharmaceuticals
XENE
$3.02B
| $133K | 0.05% |
3,673
+30
| +0.8% | +$1.09K |
|
374
Adicet Bio
ACET
$60M
| $132K | 0.05% |
9,252
+67
| +0.7% | +$956 |
|
375
Day One Biopharmaceuticals
DAWN
$773M
| $132K | 0.05% |
6,601
+50
| +0.8% | +$1K |
|